The head of the U.S. Food and Drug Administration says he is “very committed” to making progress on CBD, but his agency needs more authority to do so.
The comments by FDA Commissioner Robert Califf came Thursday during a U.S. House of Representatives budget hearing.
ADVERTISEMENT
Asked about “hemp products,” Califf noted there are an “amazing plethora of derivatives of the cannabis plant,” calling it “quite profound and astounding,” Cannabis Wire reported.
He acknowledged that hemp extracts and derivatives are “already in widespread use,” then noted that the FDA’s work to date has been focused on research to assess risks.
“I am very committed to taking a path on this,” he said.
But, for that to happen, Califf said Congress would need to give his agency more authority.
“And just to put a marker down, I don’t think the current authorities we have on the food side or
Read full article on Marijuana Business Daily